Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B in transplantation.

V G Bain1

  • 1Alberta Liver Transplant Program, Department of Medicine, University of Alberta, Division of Gastroenterology, Edmonton, Alberta, Canada. vince.bain@ualberta.ca

Transplant Infectious Disease : an Official Journal of the Transplantation Society
|June 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival.

Alimentary pharmacology & therapeutics·2009
Same author

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie·2009
Same author

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.

Alimentary pharmacology & therapeutics·2008
Same author

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.

Journal of viral hepatitis·2007
Same author

Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders.

Alimentary pharmacology & therapeutics·2007
Same author

Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials.

Alimentary pharmacology & therapeutics·2007
Same journal

Expanding the Donor Pool: Transplantation of Hepatitis B and Hepatitis C Coinfected Kidneys.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same journal

Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same journal

Expanding the Discussion on Pneumocystis jirovecii Pneumonia Prophylaxis in Non-HIV Immunocompromised Adults.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same journal

Perioperative Prophylaxis in Pediatric Solid Organ Transplantation: A Baseline Stewardship Audit Using Routine Electronic Data.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same journal

Evaluation of Cytomegalovirus (CMV) T-Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same journal

Achieving Beta-Lactam Goals During the Critical Collision of ARC in OLT Patients.

Transplant infectious disease : an official journal of the Transplantation Society·2026
See all related articles

Hepatitis B (HBV) recurrence post-transplant was a major barrier, but new antiviral strategies now allow HBV patients to be transplant candidates. Careful evaluation and tailored antiviral regimens improve outcomes and reduce recurrence risk.

Area of Science:

  • Hepatology
  • Transplantation immunology
  • Virology

Background:

  • Hepatitis B virus (HBV) recurrence post-transplant has historically excluded patients from solid organ and bone marrow transplantation.
  • Significant advancements in understanding HBV biology and developing antiviral therapies have emerged.

Purpose of the Study:

  • To review the current landscape of transplantation for patients with Hepatitis B.
  • To outline strategies for managing HBV in transplant recipients.

Main Methods:

  • Review of current literature on HBV in transplantation.
  • Analysis of antiviral strategies and their efficacy.
  • Discussion of pre-transplant evaluation and post-transplant management.

Main Results:

Related Experiment Videos

  • Patients with Hepatitis B are increasingly eligible for transplantation.
  • Tailored antiviral regimens, considering viral status and organ type, are crucial.
  • Minimizing immunosuppression, particularly steroid dose, is key to preventing viral reactivation.
  • Lamivudine has become a significant component of HBV management in transplant patients.

Conclusions:

  • Improved understanding and antiviral development have made transplantation feasible for more HBV patients.
  • Effective management relies on careful pre-transplant assessment and personalized antiviral therapy.
  • Future developments in antiviral combinations promise to further reduce recurrence and drug resistance.